Ojjaara is an once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. The approval of Ojjaara by Health ...

Ojjaara is the only once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. The approval of Ojjaara by Health Canada is supported by data from the pivotal MOMENTUM phase III trial, ...

在生命科学的浩瀚星空中，类器官技术是一颗璀璨的新星。类器官技术的出现为疾病研究、药物筛选、个性化医学研究、系统发育、组织再生等领域带来了革命性的变化。一、类器官的定义、分类及应用类器官（Organoid），是通过体外三维（3D）培养技术形成的具有特定 ...

CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Ditte S. Andersen continues, "We have identified activins as critical regulators of this process. In nutrient-restrictive conditions, activin signaling is strongly repressed, while it is reactivated ...

July 8, 2024 — By prohibiting the Activin A protein from functioning, researchers were able to halt the development of dyskinesia symptoms and effectively erase the brain's 'bad memory' response to ...

Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to ...

Analysis in melanoma cells reveals that proteolytic maturation of Activin-A is regulated by the connectivity of disulfide bonds near the furin cleavage site and stimulates tumor growth only if ...

This work is an important contribution to understanding the role of FGF signaling in the induction of primitive-like cells in a 2D system of human gastrulation. The authors provide compelling evidence ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...